5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024

Broad stock market indexes like the S&P 500 hit all-time highs in the first half of 2024.The Dow Jones Industrial Average also hit all-time highs, but saw a smaller return in the first half of the yea

Benzinga06:38

Piper Downgrades Zimmer to Neutral, Cites Lack of Catalysts

Seeking Alpha00:35

Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive in

BenzingaJul 1 23:00

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price target.

BenzingaJul 1 21:32

Johnson & Johnson Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 46.83% Cantor Fitzgerald $215 → $215 Reiterates Overweight → Overweight 06/25/2024 46.83% Canto

BenzingaJul 1 21:31

Express News | U.S. Food and Drug Administration (FDA) Approves Foundationone Liquid Cdx as a Companion Diagnostic for Akeega (Niraparib and Abiraterone Acetate) for Patients With Brca-Positive Metastatic Castration-Resistant Prostate Cancer

BreakingsJul 1 19:04